Evolus, Inc.’s (NASDAQ:) Chief Financial Officer, Sandra Beaver, recently sold company shares, resulting in a transaction exceeding $49,000. The sale, dated September 6, 2024, involved 3,276 shares of common stock at a price of $14.98 each.
This transaction was executed to cover tax withholding obligations associated with the vesting of restricted stock units. According to the filing, the shares were sold automatically through a “sell to cover” transaction, which is a common practice for handling tax obligations from equity compensation. Following the sale, Beaver’s remaining holding in the company totals 148,502 shares.
It’s noteworthy that the sale did not reflect a discretionary trading decision by Beaver, as the shares were sold solely to satisfy tax withholding requirements. The transaction details were disclosed in a Form 4 document filed with the Securities and Exchange Commission.
Investors often monitor insider transactions as they can provide insights into executives’ perspectives on their company’s stock. In this case, the transaction was not market-driven but rather a part of the standard compensation and tax fulfillment process for company insiders.
Evolus, Inc. specializes in pharmaceutical preparations and is known for its presence in the life sciences industry. The company’s shares are publicly traded under the ticker symbol NASDAQ:EOLS.
In other recent news, Evolus, Inc. reported a profitable second quarter in 2024, with a significant 36% increase in revenue from the previous year, totaling $66.9 million. Based on these results, the company revised its full-year 2024 revenue guidance upward to between $260 million and $270 million. Mizuho sustained its Outperform rating on Evolus stock, following a two-day engagement with the company’s top executives. The firm’s endorsement is based on Evolus’ unique market approach, pricing flexibility, and potential to meet its 2028 financial projections. Additionally, Evolus is preparing for the 2025 launch of its new dermal filler line, Evolysse, as part of its strategic plan to achieve a minimum of $700 million in total net revenues by 2028. However, the company’s profitability may see some fluctuations in 2025 due to the investment required for the launch of Evolysse. These are recent developments for Evolus, and more insights are expected during its Investor Day in September.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
